Skip to main content
HARBIN GLORIA PHARMACEUTICALS Co., LTD logo

HARBIN GLORIA PHARMACEUTICALS Co., LTD — Investor Relations & Filings

Ticker · 002437 ISIN · CNE100000QG8 LEI · 300300K1ZDAXM6M73U33 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,133 across all filing types
Latest filing 2022-10-26 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002437

About HARBIN GLORIA PHARMACEUTICALS Co., LTD

https://www.gloria.cc

Harbin Gloria Pharmaceuticals Co., Ltd. focuses on the research, development, manufacturing, and commercialization of diverse pharmaceutical products. The company specializes in therapeutic areas including cardiovascular and cerebrovascular diseases, orthopedics, oncology, and metabolic disorders. Its portfolio comprises chemical drugs, biological products, and specialized injections, with key products such as Alprostadil and Deer Melon Polypeptide. The organization prioritizes technological innovation through a dedicated R&D infrastructure aimed at developing both generic and innovative medications. It maintains multiple production facilities and an extensive distribution network to supply healthcare solutions for chronic and acute conditions.

Recent filings

Filing Released Lang Actions
独立董事提名人声明（杨华蓉）
Board/Management Information Classification · 95% confidence The document is a public statement from the board of directors nominating an individual as an independent director candidate. It details the nominee's qualifications, compliance with various regulatory requirements, and declarations regarding independence and eligibility. There is no financial data, no discussion of company performance, no voting results, and no mention of a meeting or report publication. The content focuses on board/management information specifically related to director nomination. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is moderate and contains detailed statements about the nominee's qualifications and compliance, consistent with a management announcement rather than a regulatory filing or report publication.
2022-10-26 Chinese
董事会议事规则（2022年10月）
Governance Information Classification · 95% confidence The document is titled as the "董事会议事规则" which translates to "Board Meeting Rules" or "Rules of Procedure for the Board of Directors" of Harbin Yuheng Pharmaceutical Co., Ltd. The content extensively details the composition, responsibilities, meeting procedures, voting rules, committees, and other governance-related aspects of the company's board of directors. There is no financial data, earnings information, or audit results presented. Instead, it focuses on internal governance structures and rules for board operations. This matches the description of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document is lengthy and substantive, not a brief announcement or a certification, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA). Therefore, the appropriate classification is CGR with high confidence.
2022-10-26 Chinese
监事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement from Harbin Yuheng Pharmaceutical Co., Ltd. regarding the resolutions of the 13th meeting of the 5th Supervisory Board. It includes approval of the 2022 third quarter report, amendments to the Supervisory Board rules, and nomination of candidates for the 6th Supervisory Board. The document references the 2022 third quarter report but does not contain the report itself or detailed financial data. It is primarily a meeting resolution announcement and governance-related information about board members and procedural rules. The document length is 3069 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, it fits best under Board/Management Information (MANG) as it deals with supervisory board meeting resolutions and nominations rather than the full quarterly report or financial statements.
2022-10-26 Chinese
关于公司董事辞职的公告
Board/Management Information Classification · 100% confidence The document is a formal announcement from Harbin Yuheng Pharmaceutical Co., Ltd. regarding the resignation of two company directors, Zhu Jiman and Bai Lihui. It details their resignation dates, reasons, shareholding information, and confirms that the resignations do not affect the board's legal minimum number. The document is an official disclosure about changes in the company's board of directors. It does not contain financial statements, audit information, or other report types. The content fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management.
2022-09-27 Chinese
关联交易管理制度
Governance Information Classification · 95% confidence The document is titled '关联交易管理制度' which translates to 'Related Party Transactions Management System'. It is a detailed internal policy document outlining the principles, scope, pricing, procedures, disclosure requirements, and approval processes for related party transactions within the company. It references relevant laws and stock exchange listing rules, and includes governance and compliance measures. There is no indication that this is a financial report, earnings release, or announcement of voting results. It is not a regulatory filing or certification letter but a governance-related document detailing internal rules and procedures. Therefore, the most appropriate classification is Governance Information (CGR). The document length (8998 characters) and content confirm it is a full policy document, not a brief announcement or report publication notice.
2022-08-28 Chinese
股东大会议事规则
Governance Information Classification · 100% confidence The document is titled as the "Shareholders' Meeting Rules" of Harbin Yuheng Pharmaceutical Co., Ltd. It details the procedures, rules, and regulations governing the conduct of shareholders' meetings, including the rights and responsibilities of shareholders, the board, and other parties involved. It does not contain financial statements, audit information, voting results, or announcements of meetings, but rather the internal rules and governance framework for conducting shareholder meetings. This aligns with the definition of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2022-08-28 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.